| 764478 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
285 Breaking through the resistance of breast cancer to immune checkpoint blockers in a unique mouse model of HR+ disease |
2021-11-01 |
10.1136/jitc-2021-sitc2021.285 |
Bloy Norma, Martinez Aitziber Buqué, Binder Bhavneet, Petroni Giulia, Yamazaki Takahiro, Sato Ai, Elemento Olivier, Formenti Silvia, Galluzzi Lorenzo |
| 764477 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
31 Serum LAG-3 is associated with improved patient prognosis in high grade serous ovarian cancer |
2021-11-01 |
10.1136/jitc-2021-sitc2021.031 |
James Nicole, Eurich Katrin, Lips Erin, Cruz Payton De La, Woodman Morgan, Ribeiro Jennifer |
| 764476 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
430 A phase 1b/II clinical study of AK112, a PD-1/VEGF bispecific antibody, in combination with olaparib in BRCA germline wild-type platinum sensitive recurrent ovarian cancer |
2021-11-01 |
10.1136/jitc-2021-sitc2021.430 |
Wu Lingying, Li Guiling, Xia Bairong, Li Rong, Wang Jing, An Ruifang, Wang Li, Li Yunxia, Song Kun, Yang Hongying, Chen Yaqing, Li Yuzhi, Huang Huiling, Jin Xiaoping, Li Baiyong, Xia Yu |
| 764475 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
189 Targeting a novel shared tumor-specific antigen with T cell receptor transduced T cells for the treatment of ovarian cancer |
2021-11-01 |
10.1136/jitc-2021-sitc2021.189 |
Ogonek Justyna, Franceschetti Tiziana, Acs Andreas, Schmidt Alexander, Kuhlenkamp Alexandra, Vincent Krystel, Perreault Claude, Loesch Barbara, Neves Adriana Turqueti, Milosevic Slavoljub, Schendel Dolores, Sommermeyer Daniel |
| 764474 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
786 Dose selection for DuoBody®-PD-L1×4-1BB (GEN1046) using a semimechanistic pharmacokinetics/pharmacodynamics model that leverages preclinical and clinical data |
2021-11-01 |
10.1136/jitc-2021-sitc2021.786 |
Bajaj Gaurav, Nazari Fereshteh, Presler Marc, Thalhauser Craig, Forssmann Ulf, Jure-Kunkel Maria, Muik Alexander, Lagkadinou Eleni, Tureci Özlem, Sahin Ugur, Ahmadi Tahamtan, Gupta Manish |
| 764473 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
785 STING-agonist ADCs targeting tumor-associated antigens coordinate immune-mediated killing of antigen-negative cancer cells |
2021-11-01 |
10.1136/jitc-2021-sitc2021.785 |
Wongthida Phonphimon, Catcott Kalli, Lancaster Kelly, Bentley Keith, Dirksen Anouk, Du Bingfan, Eitas Timothy, Kelleher Eugene, Malli Naniye, Mosher Rebecca, Protopopova Marina, Shaw Pamela, Stevenson Cheri, Thomas Joshua, Uttard Alex, Duvall Jeremy, Toader Dorin, Damelin Marc, Bukhalid Raghida, Lowinger Timothy |
| 764472 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
784 BDC-2034: discovery of a CEA-targeting immune-stimulating antibody conjugate (ISAC) for solid tumors |
2021-11-01 |
10.1136/jitc-2021-sitc2021.784 |
Mallet William, Gadkari Rishali, Pearson Cecelia, Torrez Dulgeroff Laughing Bear, Luo Angela, Luo AAngela Luondrew, Melrose Jennifer, Nolin Jess, Lee Arthur, Zhou Matthew, Anand Puneet, Sarma Ganapathy, Henning Karla, Blum Lisa, Chapin Steven, Bogaert Liz, Ackerman Shelley, Kudirka Romas, Shen Yuyi, Husain Amreen, Perez Edith, Kowanetz Marcin, Alonso Michael, Safina Brian, Dornan David |
| 764471 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
783 SGN-PDL1V, a novel, investigational PD-L1-directed antibody-drug conjugate for the treatment of solid tumors |
2021-11-01 |
10.1136/jitc-2021-sitc2021.783 |
Kwan Byron, Ramirez Megan, Jin Steven, Yu Changpu, Wo Serena, Gupta Priyanka, Allred Sean, Simmons Jessica, Hensley Kelly, Zafra Christina Zuch de, Neff-LaFord Haley, Hengel Shawna, Forero-Torres Andres, Epps Heather Van |
| 764470 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
782 PD-L1-targeted ISAC combines myeloid cell activation, immune-checkpoint inhibition and ADCP to improve anti-tumor efficacy over anti-PD-L1 antibodies in preclinical models |
2021-11-01 |
10.1136/jitc-2021-sitc2021.782 |
Kenkel Justin, Gadkari Rishali, Henning Karla, Kudirka Romas, Mallet William, Ho Po, Sarma Ganapathy, Chapin Steven, Bogaert Liz, Melrose Jennifer, Zhou Matthew, Deol Suprit, Kreder Cindy, Shen Yuyi, Anand Puneet, Lee Arthur, Li Hai, Ackerman Shelley, Safina Brian, Dornan David, Alonso Michael, Kowanetz Marcin |
| 764469 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
781 GT-001 - anti-Lewis Y antibody with superior fine-specificity and reduced off-target binding |
2021-11-01 |
10.1136/jitc-2021-sitc2021.781 |
Jaekel Anika, Kehler Patrik, Lischke Timo, Weiß Lisa, Goletz Christoph, Hartung Evelyn, Flechner Anke, Bahrke Sven, Gellert Johanna, Danielczyk Antje |
